Chung Pao Biotech Announces Board Approval of 115 Q2 Consolidated Financial Report

Disclosure Date: 1150814 Statement Date: 1150813 Statement Time: 173248 Company Code: 9917 Company Name: Chung Pao Biotech Subject: Announcement of Board Approval of 115 Q2 Consolidated Financial Report Relevant Clause: Item 31 Event Date: 1150813 Details: 1. Date reported to or resolved by the board: 115/08/13 2. Audit Committee approval date: 115/08/13 3. Reporting period of financial report or self-prepared annual financial information (YYY/MM/DD ~ YYY/MM/DD): 115/01/01 ~ 115/06/30 4. Cumulative operating revenue from January 1 to reporting period (in thousand NTD): 9,540,819 5. Cumulative gross profit (loss) from January 1 to reporting period (in thousand NTD): 3,188,873 6. Cumulative operating income (loss) from January 1 to reporting period (in thousand NTD): 1,666,302 7. Cumulative pre-tax net profit (loss) from January 1 to reporting period (in thousand NTD): 1,841,136 8. Cumulative net profit (loss) for the period from January 1 to reporting period (in thousand NTD): 1,521,012 9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to reporting period (in thousand NTD): 1,485,442 10. Cumulative basic earnings per share (loss) from January 1 to reporting period (in NTD): 3.35 11. Total assets at end of period (in thousand NTD): 31,571,878 12. Total liabilities at end of period (in thousand NTD): 18,425,920 13. Equity attributable to owners of the parent at end of period (in thousand NTD): 12,563,680 14. Other disclosures: None